MedTrace Logo

Benefit and Tolerability of IQP-LU-104 in Weight Loss

NCT03888911 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2022-08-03

No results posted yet for this study

Summary

This study is to evaluate the benefit and tolerability of two dosages of IQP-LU-104 (5120mg and 2560mg daily) in reducing body weight in overweight and moderately obese subjects

Conditions

Interventions

DIETARY_SUPPLEMENT

High dose IQP-LU-104 (5120mg)

1 sachet to be taken 2 times daily orally, together with 2 main meals

DIETARY_SUPPLEMENT

Low dose IQP-LU-104 (2560mg)

1 sachet to be taken 2 times daily orally, together with 2 main meals

DIETARY_SUPPLEMENT

Placebo

1 sachet to be taken 2 times daily orally, together with 2 main meals

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Udo Bongartz, MD, PhD · Analyze & Realize

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2019-11-21
Completion
2019-11-21

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03888911 on ClinicalTrials.gov